

Claims:

1. (Original) A method of determining the presence of an active drug in a fluid sample, said drug in its active state capable of modifying the activity level of an enzyme on a selected substrate, said method comprising the steps of:

providing a first fluid sample obtained from a patient that may or may not contain

any of said drug, said sample including said enzyme;

adding a quantity of said selected substrate to said first fluid sample;

measuring the activity level of said enzyme on said selected substrate;

comparing said measured activity level with a standard activity level established by

testing samples from individuals other than the patient that have a known

quantity of active drug present; and

determining the presence of said active drug by said measured activity level.

2. (Canceled)

3. (Original) The method of claim 2, said standard activity level representing the activity level of said enzyme on a known quantity of said selected substrate.

4. (Original) The method of claim 1 further comprising the step of correlating said measured activity level with the concentration of said active drug.

5. (Original) The method of claim 4, said correlating step including the step of comparing said measured activity level with a standard activity level.

6. (Original) The method of claim 5, said standard activity level representing the activity level of said enzyme on a known quantity of said selected substrate.

7. (Original) The method of claim 1, said enzyme activity level decreasing when said active drug is present.

8. (Original) The method of claim 1, said enzyme activity level increasing as the level of active drug in said sample decreases.

9. (Original) The method of claim 1, said enzyme activity level decreasing as the level of said active drug in said sample increases.

10. (Original) The method of claim 1, said drug being selected from the group consisting of ACE-inhibiting drugs.

11. (Canceled)

12. (Original) A method of determining the presence of active ACE-inhibiting

drugs present in a fluid sample, said ACE-inhibiting drugs in their active state being capable of modifying the activity level of a target enzyme on a selected substrate, said method comprising the steps of:

providing a first fluid sample obtained from a patient that may or may not contain

any of said ACE-inhibiting drugs;

adding a quantity of said selected substrate to said first fluid sample; [and]

determining the activity level of said target enzyme on said selected substrate in said

fluid sample at a first time to provide a base line activity level; and

comparing said base line activity level with a standard activity level established by

testing samples from individuals other than the patient that have a known

quantity of ACE-inhibiting drugs present to determine the concentration of

said active ACE-inhibiting drugs in said first fluid sample.

13. (Canceled)

14. (Original) The method of claim 12, further including the step of determining the activity level of said target enzyme on said selected substrate in said fluid sample at a second time to provide a first activity level, said second time occurring after said first time.

15. (Original) The method of claim 14, further including the step of comparing said base line activity level with said first activity level.

16. (Currently Amended) The method of claim 14, further including the step of comparing said first activity level with [a] said standard activity level.

17. (Original) The method of claim 12, further including the steps of:
providing a second fluid sample;
adding a quantity of said selected substrate to said second fluid sample; and
determining the activity level of said target enzyme on said selected substrate in said
second fluid sample to provide a second activity level.

18. (Original) The method of claim 17, further including the step of comparing said first activity level with said second activity level.

19. (Original) The method of claim 12, said first fluid sample comprising urine.

20. (Original) The method of claim 12, said base line level of activity being representative of said target enzyme's activity when no ACE-inhibiting drugs are present.

21. (Canceled)

22. (Original) The method of claim 12, said ACE-inhibiting drugs being selected from the group consisting of benazepril, captopril, enalapril, fosinopril, lisinopril, quinapril, ramipril,

and trandolapril and combinations thereof.

23. (Original) The method of claim 12, said determining step including the step of measuring the optical density of said fluid sample.

24. (Original) The method of claim 12, said activity levels being correlated with the optical density at 340 nm.

25-51. (Canceled)